Takafumi Yamamoto

12PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 05, 2026
Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.

|Nov 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Nov 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Takanori Ito, Shigeo Shimose, Issei Saeki

|Aug 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Takeshi Hatanaka, Shigeo Shimose, Takanori Ito

|May 15, 2025
Steroid initiation dose and duration of steroid reduction for immune checkpoint inhibitor-induced liver injury.

Takafumi Yamamoto, Takanori Ito, Takaya Suzuki

|May 03, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Takanori Ito, Shigeo Shimose, Joji Tani

Pageof 2

Frequent Collaborators

5 joint publications

Takumi Kawaguchi

5 joint publications

Hideki Iwamoto

5 joint publications

Takeshi Hatanaka

5 joint publications

Taro Takami